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A B S T R A C T
Background: Two implantable continuous-ﬂow left ventricular assist devices (LVADs), DuraHeart
(Terumo Heart, Ann Arbor, MI, USA) and EVAHEART (Sun Medical, Nagano, Japan), were approved in
Japan in April 2011. We analyzed the midterm outcome of patients implanted with these implantable
LVADs at the University of Tokyo Hospital.
Methods and results: A total of 31 patients who underwent implantation of LVADs (10 DuraHeart, 21
EVAHEART) as a bridge to transplantation at our institution between April 2011 and August 2013 were
retrospectively reviewed. All patients were followed up through December 2013. Seven patients
underwent conversions from NIPRO paracorporeal LVAD (Nipro, Osaka, Japan) to an implantable LVAD.
The mean observation period was 483  239 days (41.0 patient years). Eight patients were transplanted
and one patient showed functional recovery with subsequent LVAD explantation. Four patients died due to
cerebrovascular accident, empyema, or device malfunction due to pump thrombosis after cerebral bleeding.
Kaplan–Meier analysis revealed 6-, 12-, and 24-month survival rates of 93%, 86%, and 86%, respectively. The
rates of freedom from cerebrovascular accidents and device-related infections at 1 year after LVAD
implantation were 65% and 36%, respectively. Twenty-nine patients were discharged home after LVAD
implantation. During the period of this study, there were 59 readmissions (53 urgent, 6 elective) among 22
patients (76%). The overall and urgent readmission rates were 1.66 and 1.49 per patient year, respectively.
The common reason for readmission was device-related infection (31%), followed by cerebrovascular
accidents (17%). The total out-of-hospital time after the primary discharge was 90%.
Conclusions: Our midterm survival rate after LVAD implantation is satisfactory. However, patients
undergoing LVAD support were often readmitted with adverse events.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Heart transplantation is a comprehensive solution for patients
with end-stage heart failure, but it is available for only a small
fraction of these patients because of serious donor shortages [1].
Several types of continuous-ﬂow implantable devices have
demonstrated signiﬁcantly improved clinical results and left
ventricular assist devices (LVADs) are increasingly used for
destination therapy. reserved.
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2 years [2,3]. Approximately 90% of Japanese recipients currently
required LVAD support as a bridge to transplantation. NIPRO LVAD
(Nipro, Osaka, Japan), a paracorporeal pneumatic device, was
formerly the only choice for patients with end-stage heart failure
in Japan [4]. Two implantable centrifugal pumps, DuraHeart
(Terumo Heart, Ann Arbor, MI, USA) [5,6] and EVAHEART (Sun
Medical, Nagano, Japan) [7,8], were approved by the Japanese
Ministry of Health, Labour and Welfare in April 2011 [9].
HeartMate II axial pump (Thoratec Corp., Pleasanton, CA, USA)
[10] was also approved in April 2013. These devices are expected to
reduce pump-related morbidity and improve quality of life in
patients undergoing LVAD support [11].
According to the Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) report, which includes
data on more than 6000 implants, current 1-year survival rate
with a continuous-ﬂow LVAD is 80% [12]. This study included
destination therapy as well as bridge to transplant [13], and in
which HeartMate II was the most frequently implanted device.
Because only centrifugal pumps were available until March 2013
and only for bridge to transplant, an outcome of continuous-ﬂow
LVADs in Japan might be different from the INTERMACS report.
The Japanese registry for Mechanically Assisted Circulatory
Support (J-MACS) database, in which all implantable LVADs
treatment facilities participate in Japan, revealed that 1-year
survival rate of implantable LVADs was 87% in Japan [14].
Considering an increasing number of patients with LVAD
supports, causes and outcomes of readmissions are also of
interest [15,16]. However, there are few reports on these
outcomes of implanted LVADs in Japan [14,17]. Therefore, in
this retrospective study, we analyzed the midterm outcomes of
patients implanted with centrifugal pumps at the University of
Tokyo Hospital.
Methods
Patients and study design
There were 37 consecutive patients with end-stage heart
failure who received implantable LVADs as a bridge to
transplantation between April 2011 and August 2013 at the
University of Tokyo Hospital. All patients provided written
informed consent before LVAD implantation. The study period
was divided into 3 periods. Period A was a time between April
2011 and the middle of December 2011, in which both DuraHeart
and EVAHEART were available without restriction. Period B was a
time between the end of December 2011 and April 2013, in which
DuraHeart was not available except for exceptional usage. Period
C was a time between May 2013 and August 2013. In our
institution, HeartMate II was approved in May 2013. DuraHeart
implantation was recommenced from the end of July 2013.
Twelve, seventeen, and eight LVAD implantations were per-
formed in Periods A, B, and C, respectively. During Period A, we
selected DuraHeart if the patients’ body surface area were
1.50 m2 or less. The patients who underwent LVAD implantation
during Period B received EVAHEART except one DuraHeart
exceptional usage. During Period C, we selected HeartMate II for
the patients with body surface area 1.55 m2 or less, and the
centrifugal pumps for those with right heart failure preopera-
tively. A total of 6 of the 37 patients with LVAD implantation
received HeartMate II device and were excluded from this study
because the observation periods were shorter than that for the
other devices. We retrospectively evaluated the 31 patients.
These 31 patients received either DuraHeart or EVAHEART and
were followed up through December 2013. Seven patients
underwent conversion from NIPRO paracorporeal LVAD to animplantable LVAD. No patient with an implantable LVAD
required a right ventricular assist device perioperatively.
Patients with DuraHeart received anticoagulation therapy with
warfarin with a target international normalized ratio of
prothrombin time (PT-INR) of 2.3–2.8, and patients with
EVAHEART received warfarin with a target PT-INR of 2.8–3.5.
The patients with an implantable LVAD also received antiplatelet
therapy with aspirin 100 mg per day. Dipyridamole 300 mg per
day was administered to the patient with a history of embolism.
Once critical cerebral bleeding occurred the anticoagulation
therapy was reversed fully, and heparin was started at 72 h after
the hemorrhage unless active bleeding. After hospital discharge,
LVAD recipients were followed up by monthly outpatient visits
or, if necessary, more frequently.
Clinical data included demographic proﬁles, adverse events,
readmissions, and outcomes. Deﬁnition of adverse events was
based on the J-MACS adverse events. Bleeding was categorized as
postoperative bleeding requiring re-operation or gastrointestinal
bleeding requiring transfusion of red blood cells. Ventricular
arrhythmia was deﬁned as a sustained ventricular arrhythmia
requiring deﬁbrillation or cardioversion. A cerebrovascular acci-
dent was deﬁned as an ischemic or hemorrhagic intracranial event
that persisted beyond 24 h or lasted less than 24 h with infarction
on an imaging study. A device-related infection was categorized as
either (1) a driveline infection, which was localized to the tissue
surrounding the driveline accompanied by pain, fever, drainage, or
leukocytosis, and treated with nonprophylactic antimicrobial
agents, or (2) a pump pocket infection, which involved the tissue
surrounding a pump within the body or mediastinal tissue along
the inﬂow or outﬂow tract, coupled with the need for antimicrobial
therapy. Sepsis was deﬁned as systemic infection evidenced by a
positive blood culture that was treated with antimicrobial agents
with or without a device-related infection. A device malfunction
was deﬁned as a failure of one or more of the components of the
mechanical cardiac support device system that directly caused or
could potentially induce a state of inadequate circulatory support
or death.
Statistical analysis
We performed statistical analyses with IBM SPSS Statistics
version 21.0 (IBM Corp., Armonk, NY, USA). Continuous variables
are expressed as mean  standard deviation or mean/median
(range). Cumulative survival curves and actuarial freedom from the
ﬁrst event, such as a cerebrovascular accident, device-related
infection, or readmission, were computed using the Kaplan–Meier
method. Patients were censored in case of transplantation or recovery
with device explantation, or on 31 December 2013.
Results
Baseline patient characteristics
The baseline characteristics of 31 patients are listed in Table 1. A
total of 10 patients received DuraHeart (32%), and 21 received
EVAHEART (68%). Seven patients underwent conversions from
NIPRO paracorporeal LVAD to an implantable LVAD. The median
interval from a paracorporeal LVAD to an implantable LVAD was
115 days (60–279 days). An LVAD was necessary in 23 patients
with idiopathic dilated cardiomyopathy, in 4 patients with
ischemic cardiac disease, and in 3 patients with dilated phase
hypertrophic cardiomyopathy. All patients who were categorized
as preoperative INTERMACS proﬁle 1 underwent NIPRO LVAD
implantation and subsequently conversion surgery. A patient who
was categorized as INTERMACS proﬁle 4 had suffered from
frequent ventricular tachycardia preoperatively.
Table 1
Baseline patient characteristics.
Total (N = 31)
Age (years) 39.7  11.7
Male 21 (84%)
Body surface area (m2) 1.67  0.14
Etiology of heart failure
Idiopathic dilated cardiomyopathy 23 (74%)
Dilated phase hypertrophic cardiomyopathy 3 (10%)
Ischemic cardiomyopathy 2 (6%)
Cardiogenic shock due to AMI 2 (6%)
Post myocarditis 1 (3%)
Type of LVAD
DuraHeart 10 (32%)
EVAHEART 21 (68%)
Conversion from NIPRO LVAD 7 (23%)
INTERMACS proﬁle
Proﬁle 1 6 (19%)
Proﬁle 2 14 (45%)
Proﬁle 3 10 (32%)
Proﬁle 4 1 (3%)
Data given as mean  SD or n (%).
AMI, acute myocardial infarction; LVAD, left ventricular assist device; INTERMACS,
Interagency Registry for Mechanically Assisted Circulatory Support.
Table 3
Deceased patient characteristics.
Patient no. 1 2 3 4
Age (years) 45 42 53 49
Sex Male Female Male Male
Body surface area (m2) 1.72 1.48 1.56 1.55
Etiology of heart failure DCM AMI dHCM p-carditis
Type of LVAD EVAHEART EVAHEART EVAHEART EVAHEART
Conversion from
NIPRO LVAD
No Yes No No
INTERMACS proﬁle 2 1 3 3
LVAD support time
(days)
342 17 265 164
Cause of death Pump
thrombosis
CVA Empyema CVA
DCM, idiopathic dilated cardiomyopathy; AMI, acute myocardial infarction;
dHCM, dilated phase hypertrophic cardiomyopathy; p-carditis, post myocardi-
tis; LVAD, left ventricular assist device; INTERMACS, Interagency Registry for
Mechanically Assisted Circulatory Support; CVA, cerebrovascular accident.
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Table 2 summarizes the clinical outcomes after LVAD surgery.
The postoperative observation period was 483  239 days (41.0
patient years). Following LVAD implantation, 8 patients were
transplanted and 1 patient showed functional recovery with
subsequent LVAD explantation [18]. Mean implantable LVADs
support time of the 8 patients who underwent heart transplantation
was 720 days (453–945 days). Four patients died after LVAD
implantation. The causes of death were cerebrovascular accident,
empyema, and device malfunction due to pump thrombosis after
cerebral bleeding. The details of the four patients are shown in
Table 3. The remaining 18 patients underwent ongoing LVAD support.
The 6-, 12-, and 24-month survival rates of the patients with
implanted LVADs were 93%, 86%, and 86%, respectively (Fig. 1).
The most common adverse events following LVAD implantation
are shown in Table 2. During the study period 27 cerebrovascular
accidents among 13 patients occurred. A total of 23 of the 27
cerebrovascular events were ischemic and the other 4 were
hemorrhagic events. There were 18 cerebral infarctions in patients
with EVAHEART. The rates of freedom from cerebrovascular
accidents at 1, 6, and 12 months after LVAD implantation were
84%, 77%, and 65%, respectively. Eighteen patients experienced
complications of device-related infection. One of these patientsTable 2
Clinical outcome after left ventricular assist device implantation.
Total (N = 31)
Outcome
Transplanted 8 (26%)
Weaned from LVAD support 1 (3%)
Died 4 (13%)
Ongoing LVAD support 18 (58%)
Adverse events
Postoperative bleeding 2 (6%)
Gastrointestinal bleeding 0 (0%)
Ventricular arrhythmia 5 (16%)
Cerebrovascular accident 13 (42%)
Device-related infection 18 (58%)
Sepsis 8 (26%)
Data given as n (%).
LVAD, left ventricular assist device.developed a pump pocket infection and underwent negative-
pressure wound therapy and omental transposition [19]. The rates
of freedom from device-related infections at 1, 6, and 12 months
after LVAD implantation were 97%, 65%, and 36%, respectively.
Freedom curves from cerebrovascular accidents and device-related
infections are shown in Fig. 2. Eight patients developed sepsis. The
most frequent responsible bacterium was Staphylococcus aureus,
which was detected in 6 of the 8 sepsis patients. Ventricular
arrhythmia was also a major adverse event. The patients with
implantable LVADs who developed ventricular arrhythmia and
unexperienced loss of consciousness needed deﬁbrillation or
cardioversion in the emergency room. No patients developed
gastrointestinal bleeding requiring blood transfusion. In 28
patients, von Willebrand factor (vWF) ristocetin cofactor activity
(vWF:Rco) was measured at 6–12 months after LVAD implanta-
tion, and vWF:Rco was 60% or less in 4 patients.
Readmission after discharge
Twenty-nine patients were discharged home after LVAD
implantation. Two patients died before discharge. The medianFig. 1. Kaplan–Meier model of survival after left ventricular assist device (LVAD)
implantation.
Fig. 2. Actuarial freedom from cerebrovascular accidents (A) and device-related infections (B) in patients who underwent left ventricular assist device (LVAD) implantation.
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observation period after primary discharge was 448  227 days
(35.6 patient years). During this time, there were 59 readmissions
among 22 patients (76%). The readmissions were categorized as
urgent in 53 cases and elective in 6 cases. The overall and urgent
readmission rate was 1.66 and 1.49 per patient year, respectively.
Freedom curve from urgent readmission appears in Fig. 3. The rates of
freedom from urgent readmission at 1, 6, and 12 months after
discharge were 86%, 46%, and 29%, respectively. The most common
etiology was device-related infection, accounting for 31% of the
readmissions, followed by cerebrovascular accidents (17%). Headache
and/or dizziness, which were difﬁcult to differentiate from cerebro-
vascular accidents, were also common reasons for readmission. Two
patients were readmitted because of device malfunction. One patient
received a controller exchange urgently, and the other accidentally
detached bilateral battery at the same time. The most common reason
for elective readmissions was cardiac catheterization, which wasFig. 3. Actuarial freedom from ﬁrst readmission after primary hospitalization in patient
readmission (B).performed to evaluate the effect of pulmonary vasodilators [20]. The
median length of stay after readmission was 14 days (1–168 days)
(Fig. 4). The total out-of-hospital time after the primary discharge
was 90%.
Discussion
In the present study, we reported our institutional experience
with implantable centrifugal pumps in a series of 31 patients after
a mean follow-up of 484 days. The 1- and 2-year survival rates after
LVAD implantation were 86% and 86%, respectively. Two centrifu-
gal pumps were used in our study. They were the only devices that
were approved by the Japanese Ministry of Health, Labour and
Welfare until March 2013. The J-MACS reported that 1-year
survival rate of implantable LVADs was 87% in Japan [14]. J-MACS
report was similar to our study in patients’ baselines, device types,
indications, and survival rate. According to the INTERMACS reports who underwent left ventricular assist device (LVAD) implantation (A). Reason for
Fig. 4. Length of stay during readmissions for each etiology.
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80% [12]. European results of continuous-ﬂow LVAD implantation
showed 1-year survival rate of 72% [21]. These databases included
destination therapy.
Our study included 7 patients who underwent conversion from
NIPRO paracorporeal LVAD to an implantable LVAD. The conver-
sion from paracorporeal LVAD to an implantable LVAD is an
important strategy for patients who have not yet been approved by
the Heart Transplant Recipient Advisory Council at each institution
[22,23], because those patients are not currently permitted to use
an implantable LVAD in Japan [24]. In the present study, all
patients who underwent a conversion procedure experienced a
rapid onset of heart failure, and needed LVAD support before listing
for heart transplantation. They were categorized as INTERMACS
proﬁle 1 or 2. In this study, 3 of the 7 patients with conversion from
NIPRO LVAD received DuraHeart, and the others received
EVAHEART. In Period A, all patients with conversion procedure
received DuraHeart, because the NIPRO apical cuff size was the
same as that of DuraHeart [23]. During Period B, we performed
conversion to both DuraHeart and EVAHEART. Yoshioka et al. [23]
reported that some patients who developed infections of the
NIPRO LVAD exit site suffered pump pocket infections after the
conversion procedure. Therefore, patients with serious infections
of the NIPRO LVAD exit site do not undergo conversion to an
implantable LVAD in our institution. In the present study, no
patient with conversion surgery had active infection of the exit
sites before the procedure. None of them developed pump pocket
infections. Prevention of infection at the exit site before the
conversion procedure is mandatory for patients who undergo
NIPRO LVAD implantation.
In the present study, 42% of the patients who underwent LVAD
implantation developed cerebrovascular accidents (0.66 events
per patient year). Nakajima et al. [25] reported that 48% of thepatients who underwent LVAD implantation developed cerebro-
vascular accidents. Sakaguchi et al. [17] reported a lower
cerebrovascular accident rate of 17%. However, these stroke rates
were higher than those in the INTERMACS report. The rates of
freedom from stroke at 1 month and 1 year were 97% and 89%,
respectively, and only 9% of the patients who underwent
continuous-ﬂow LVAD implantation developed stroke according
to the INTERMACS report [12]. In the present study, cerebrovascu-
lar events included minor symptoms with infarction on head
computed tomography according to J-MACS deﬁnitions. In Japan,
imaging studies are performed relatively many times. They may
pick more events up, and our stroke rate may be higher than the
USA. In this study, there were 7 patients with permanent damage
from a cerebrovascular accident or dying of a cerebrovascular
accident. Dell’Aqila et al. [26] reported that the rate of freedom
from stroke at 1 month after HeartWare (HeartWare International
Inc, Framingham, MA, USA) ventricular assist device implantation
was 48% in patients with an INTERMACS proﬁle 1 and 2, and 81% in
patients with an INTERMACS proﬁle 3 and 4. The development of
cerebrovascular accidents after LVAD implantation may be
signiﬁcantly affected by the device type [27]. There were 18
cerebral infarctions in patients with EVAHEART, and mean PT-INR
was 2.83  0.83 at the events. PT-INR values were less than 2.00 at 6
of the 18 events, and more than 3.00 at 6 events. Ischemic events did
not always occur during insufﬁcient anticoagulation therapy. In the
present study, the ﬁrst 5 of the 13 cerebrovascular accidents occurred
within 1 month after LVAD surgery. Lahpor et al. [21] reported that
neurological complications occurred in the ﬁrst 6 weeks following the
implantation in a European multicenter study. Our study also
suggests that cerebrovascular accidents are more likely to develop
in the early period after LVAD implantation. Starling et al. [28]
reported that the risk of pump thrombosis of HeartMate II peaked
within 1 month after implantation and then fell after 6–8 months.
This result suggested that the risk of embolic disease also peaked in
the early period after LVAD implantation.
Infectious complications are also a major problem in patients
under LVAD support. Sakaguchi et al. [17] reported that 34%
patients developed device-related infections. In the present study,
17 patients (55%) developed device-related infections, and the rate
of freedom from device-related infections at 1 year after LVAD
implantation was 40%. In 12 of the 17 patients who developed
device-related infections, the infections occurred more than 150
days after LVAD implantation. This result was a contrast to
cerebrovascular accidents, which were likely to occur in the early
postoperative period. Sharma et al. [29] reported that a longer
duration of LVAD support signiﬁcantly increased the risk of
driveline infections. Our result was similar to their report. One of
the 17 patients developed a pump pocket infection [19], and the
other 16 patients developed a driveline infection. Surgical
debridement followed by negative pressure wound therapy in a
driveline exit site was performed for one patient. Five of the
seventeen patients (29%) underwent chronic suppressive antimi-
crobial therapy. Nienaber et al. [30] reported that 14% of the
patients with device-related infections had surgical debridement
and 42% of the patients were managed by chronic suppressive
antimicrobial therapy.
No patients in the present study developed gastrointestinal
bleeding. This result was in contrast to that of US and European
multicenter studies [21,31]. In these trials, gastrointestinal
bleeding was a major adverse event, and the most common
etiology for readmissions [15,16]. The relationship between
acquired von Willebrand disease and axial-ﬂow LVADs was
pointed out [32]. However, low vWF:Rco was demonstrated in a
few patients in our study. All patients in this study were implanted
centrifugal pumps, and centrifugal pump may suffer less with
acquired von Willebrand disease [7].
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EVAHEART. Three quarters of deaths were related to cerebrovas-
cular accidents. The rates of cerebrovascular accidents with
DuraHeart and EVAHEART were 0.32 and 0.86 per patient year,
respectively. The patients with EVAHEART may have suffered from
thromboembolic events more frequently than with DuraHeart.
However, it was difﬁcult to discuss the difference between the two
devices because of the small number of patients in this study. It
needs a study in a large number of patients to evaluate the
difference between the two devices.
In our study, there were 59 readmissions among 22 patients
(76%). The overall and urgent readmission rates were 1.66 and 1.49
per patient year, respectively. In the Mayo Clinic, the readmission
rate was 1.64  1.97 per patient year for patients who underwent
HeartMate II implantation [16]. In our study, 53 readmissions (88%)
were urgent. Forest et al. [15] reported that 87% of the readmissions
were urgent. The result of our study was similar to that of these US
studies using HeartMate II. However, the causes of readmission were
slightly different between our study and the US studies. The most
common etiology of readmissions was gastrointestinal bleeding in
the HeartMate II studies and device-related infection (34%) in our
study. Cerebrovascular accidents (17%) were also a major cause of
readmissions. Although there was no evidence of ischemic or
hemorrhagic changes on imaging studies, follow-up with readmission
was needed for patients with headache and/or dizziness in 4 cases.
Ventricular arrhythmia occurred in 5 patients, and 2 of these 5
patients visited the emergency room frequently. Raasch et al. [33]
reported that patients with post-LVADs implant ventricular arrhyth-
mias had a higher rehospitalization rate. In the present study, 2 patients
were readmitted more than 3 times for ventricular arrhythmias.
Prompt treatment was required at the time of urgent read-
missions, especially in patients with cerebrovascular accidents,
ventricular arrhythmias, and device malfunctions. Neurologists or
neurosurgeons are needed for patients with cerebrovascular
accidents. Clinical engineers or perfusionists trained for an
implantable LVAD are needed for patients with device malfunc-
tion. We should make an effort to reduce the adverse events so as
not to increase the number of readmissions after LVAD implanta-
tion. At the same time, we should also establish a system for
properly handling the increase in the number of readmissions by
ensuring sufﬁcient human and material resources.
In our study, mean implantable LVADs support period of the
patients who underwent heart transplantation was 720  171
days. They stayed out-of-hospital during 79% (47–94%) of the LVADs
support period, and some of them worked during the waiting period.
Limitations
Our study has several limitations. This study is a descriptive
retrospective analysis and not hypothesis-driven. This study also
included a limited number of patients. The follow-up periods were
short. It was conducted in a single center, and it may not be
representative of what occurs at other centers.
Conclusions
Our initial results demonstrated that midterm survival rate
after LVAD implantation is satisfactory. However, patients
undergoing LVAD support were often readmitted with adverse
events, such as device-related infections, cerebrovascular acci-
dents, and ventricular arrhythmia.
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